Tumor Suppressor Gene Located In Liver Cancer Cells

April 29, 1996

DURHAM, N.C. -- A malfunctioning "traffic cop" gene apparently plays an important role in the formation of liver cancer, according to researchers from the Duke University Comprehensive Cancer Center and Zeneca Pharmaceuticals of Chesire, United Kingdom.

The discovery that the gene -- mannose 6-phosphate/insulin-like growth factor II receptor, or M6P/IGF2r -- acts as a tumor suppressor gene in human liver tumors could help researchers develop an early diagnostic test for liver cancer as well as new treatments, the researchers said. The disease is often far advanced at detection, and the five-year survival rate in the United States is only 4 percent.

A report on this tumor suppressor gene appears in the December issue of Nature Genetics. Along with principal investigator Randy Jirtle, Gerald R. Hankins and Mary K. Washington of Duke University Medical Center; and Angus T. De Souza and Terry C. Orton of Zeneca are co-authors.

Funding for the project came from the National Institutes of Health, Zeneca, the Proctor and Gamble Co. and MITRE Corp.

"Liver cancer is one of the most common cancers worldwide, particularly because of its association with viral hepatitis," said Jirtle, a professor of radiation oncology and cancer center member. The lack of effective treatments also makes it a particularly deadly disease, he said.

"As a consequence, knowing something about liver tumor formation or having a handle on how one could detect these tumors when they're much smaller could have a significant impact on survival," he said.

The protein receptor produced by M6P/IGF2r is an attractive target because it is present on the cell surface and in the plasma, Jirtle said, making it readily accessible for use in both liver tumor therapy and diagnosis.

Researchers often work backwards from the biological changes involved in cancer to find the genes responsible for these alterations. In this case, however, the functions of an already-identified gene led Jirtle and his team to hypothesize its involvement in liver cancer.

"This is an 'old' gene for which we have characterized an important new role," Jirtle said.

When working properly, the M6P/IGF2r receptor protein has at least three distinct regulatory -- or "traffic cop" -- roles within a cell, said Jirtle. It is involved in activating a very potent growth inhibitor, called ³transforming growth factor beta.² It disables a positive growth factor, ³insulin-like growth factor II.² The receptor also works inside the cell as a shuttle craft, moving proteolytic enzymes to the lysosomes, a part of the cellular digestive system that breaks down proteins into simpler compounds.

Because the receptor is involved both in switching on a growth inhibitor and inactivating a growth factor, the researchers hypothesized that losing it might well predispose a cell to cancerous growth. Their past studies showing that the protein was abundantly present in normal liver cells, but nearly absent in cancer cells, strengthened their suspicion.

In research published earlier this year in the journal Oncogene, Jirtle's team found that liver tumors from 64 percent of patients studied had lost one copy of the gene. The deletion of one copy, or allele, means that a mutation in the remaining copy can limit or destroy a cell's ability to produce functional protein.

Next, the researchers began the arduous process of screening the large gene for one or more mutations that might disable it. Using a method to detect mismatches in genetic material, they compared strands of DNA from tumor cells and surrounding normal tissue, and discovered mutations in the tumor samples. The discovery of identical mutations in more than one tumor indicated potential "hot spots" -- regions of the gene that may be more susceptible to mutation.

"One mutation results in an altered protein that lacks the ability to insert itself into the cell membrane," according to Zeneca's De Souza, who has spent three years at Duke University investigating this gene. "Instead of carrying out its normal regulatory functions, this shortened protein leaves the cell. Once outside, it can no longer regulate cell growth."

The gene is also interesting to researchers because it could help to explain why mice appear to be more prone to liver tumor formation than humans. Mice normally have only one active copy of this tumor suppressor gene rather than the two working copies humans possess. This evolutionary oddity could have important implications for species susceptibility to liver tumors and human risk assessment.

Animals and humans have two functional copies of almost every gene, one from each parent. In rare cases, a gene is imprinted, meaning that only one of the parental copies is active. The M6P/IGF2r is especially unusual, because it is imprinted in mice but not in humans. Lacking the back-up that humans have in case one copy malfunctions, mice are more likely to lose complete function of this gene, the researchers said.

If further studies show that loss of the M6P/IGF2r function is important in the way chemicals cause liver tumors in rats, the scientists explained, then pharmaceutical companies could take into account the decreased likelihood of this genetic loss occurring in humans when determining whether to pursue the testing of a promising new drug.

Jirtle and his colleagues are continuing their studies of the M6P/IGF2r by investigating whether this gene also plays a role in the formation of other types of tumors. After four years of study, Jirtle said, "We are at the end of the beginning."

Duke University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.